Changeflow GovPing Pharma & Drug Safety Omnicell Syringe Labels May Cause Mislabeling o...
Urgent Enforcement Amended Final

Omnicell Syringe Labels May Cause Mislabeling on i.v.STATION

Favicon for www.fda.gov FDA MedWatch Safety Alerts
Detected
Email

Summary

The FDA is alerting healthcare providers about Omnicell syringe labels used with the i.v.STATION automated compounding system that may cause mislabeling. Omnicell issued a letter on April 10 recommending affected customers remove and discontinue use of specific sterile syringe labels. The issue involves inconsistent label detection behavior across i.v.STATION printers that could result in unlabeled or mislabeled syringe preparations. No serious injuries or deaths have been reported as of the notification date. Healthcare providers should immediately segregate affected labels and contact Omnicell Technical Support.

“Inconsistent label detection could result in unlabeled or mislabeled syringe preparations after compounding completion where the above identified sterile labels are utilized.”

FDA , verbatim from source
Published by FDA on fda.gov . Detected, standardized, and enriched by GovPing. Review our methodology and editorial standards .

About this source

GovPing monitors FDA MedWatch Safety Alerts for new pharma & drug safety regulatory changes. Every update since tracking began is archived, classified, and available as free RSS or email alerts — 16 changes logged to date.

What changed

Omnicell has issued a letter recommending removal of specific IVSTATION SYRINGE sterile labels (part numbers 258920028 and 258920029) due to inconsistent label detection behavior across i.v.STATION printers. The FDA Early Alert warns that this defect could result in unlabeled or mislabeled syringe preparations after compounding completion. Affected healthcare providers using i.v.STATION automated compounding systems must immediately cease use of the affected sterile labels, revert to non-sterile yellow-backed labels, and implement heightened pharmacist verification. As of April 10, no serious injuries or deaths have been reported.

What to do next

  1. Do not use labels affected by this recall. If you or your staff locate any affected labels, immediately segregate and contact Omnicell Technical Support.
  2. Revert to the use of previously ordered non-sterile syringe labels with yellow backing (part number HR060027 and HR060071).
  3. Engage in vigilant pharmacist verification practices to verify the accuracy of labels per your existing review process.

Archived snapshot

Apr 24, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.


CDRH is issuing this Early Alert **to notify the public of a potentially high-risk device issue.* The FDA will keep the public informed and update this web page as significant new information becomes available.*

Affected Product

The FDA is aware that Omnicell has issued a letter to affected customers recommending certain syringe labels used with the i.v.STATION automated compounding system be removed from where they are used or sold.

Affected devices:

  • IVSTATION SYRINGE sterile label (40MMX40MM) - part number 258920028
  • IVSTATION SYRINGE sterile label (20MMX40MM) - part number 258920029 These labels come individually wrapped in a plastic overwrap with a white backing.

What to Do

Do not use affected labels. Verify accuracy of labels on filled products.

On April 10, Omnicell sent all affected customers a letter recommending the following actions:

  • Do not use labels affected by this recall. If you or your staff locate any affected labels, immediately segregate and contact Omnicell Technical Support.
  • Revert to the use of previously ordered non-sterile syringe labels with yellow backing (part number HR060027 and HR060071).
  • Engage in vigilant pharmacist verification practices to verify the accuracy of labels per your existing review process.
  • Share this information with all those who need to be aware within your organization. Check this web page for updates. The FDA is currently reviewing information about this potentially high-risk device issue and will keep the public informed as significant new information becomes available.

Reason for Alert

Omnicell received a report of mislabeling that could affect sterile syringe labels produced using i.v.STATION. Omnicell identified inconsistent label detection behavior across i.v.STATION printers when using the sterile labels affected by this recall.

Inconsistent label detection could result in unlabeled or mislabeled syringe preparations after compounding completion where the above identified sterile labels are utilized.

As of April 10, Omnicell has reported no serious injuries or deaths associated with this issue.

Device Use

i.v.STATION is an automation device that limits the need to manually handle vials, solutions, IV bags, and syringes during the preparation and compounding of IV medications, while also minimizing cross-contamination between drugs.  As part of the device's automation, it applies labels to compounded preparations for identification and traceability.

Contact Information

Customers in the U.S. with adverse reactions, quality problems, or questions about this issue should contact Omnicell at 817-3574904.

How do I report a problem?

Health care professionals and consumers may report adverse reactions or quality problems they experienced using these devices to MedWatch: The FDA Safety Information and Adverse Event Reporting Program.

  • ## Content current as of:

04/24/2026

  • Regulated Product(s)

    • Medical Devices

Parties

Get daily alerts for FDA MedWatch Safety Alerts

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from FDA.

What's AI-generated?

The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.

Last updated

Classification

Agency
FDA
Instrument
Enforcement
Branch
Executive
Legal weight
Binding
Stage
Final
Change scope
Substantive

Who this affects

Applies to
Healthcare providers Medical device makers
Industry sector
3345 Medical Device Manufacturing
Activity scope
Product recall response Label verification
Geographic scope
United States US

Taxonomy

Primary area
Medical Devices
Operational domain
Clinical Operations
Topics
Healthcare Product Safety

Get alerts for this source

We'll email you when FDA MedWatch Safety Alerts publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!